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In this issue of Cancer Cell, Zunder et al. (2008) describe surprising findings from investigating inhibitor-
resistant mutations in the affinity pocket of p110a of phosphatidylinositol 3-kinase (PI3K). Information on
these critical residues provides a road map for generating novel PI3K inhibitors that can overcome the
anticipated resistance mutations.Small-molecule inhibitors targeting the
tyrosine kinases Abl and EGFR have
been spectacularly successful as cancer
drugs (Druker, 2004). However, these
successes have been curtailed by the
appearance of kinase mutants that are
resistant to the inhibitors (Gorre et al.,
2001; Pao et al., 2005). The inhibitors typ-
ically bind to a conserved structural motif,
referred to as an affinity pocket, that is
located in the immediate vicinity of the
ATP binding site. They compete with ATP
for binding to the kinases. Most of the
resistance mutations block inhibitor bind-
ing. A particularly effective and commonly
encountered mutation occurs at a position
referred to as the ‘‘gatekeeper’’ that con-
trols access of inhibitors to the affinity
pocket. The resistance mutations have
now led to the development of second-
generation inhibitors that are effective
against many of the mutant kinases (Bur-
gess and Sawyers, 2006; Druker, 2006;
Kwak et al., 2005). However, targeting
gatekeeper mutant kinases remains a
significant challenge. This situation illus-
trates the general problem of mutation-
induced drug resistance that needs to be
anticipated in all therapeutic strategies.
In recent years, phosphatidylinositol
3-kinase (PI3K) has emerged as an ex-
ceedingly attractive and promising drug
target. The PI3K signaling pathway is
upregulated in most cancers as a resultof various genetic and epigenetic changes.
PIK3CA, the gene encoding the catalytic
subunit p110a of PI3K, is frequently mu-
tated in cancers of the breast, colon,
endometrium, and prostate (Samuels
et al., 2004). About 80% of these muta-
tions map to one of three hot spots in
the gene. They induce a gain of function
in enzymatic and signaling activity. The
mutant p110a is also oncogenic in cell
culture and in animal model systems,
strongly suggesting that it contributes to
the oncogenic cellular phenotype in hu-
man cancers. Academic and industrial
laboratories have responded to this de-
velopment by generating PI3K inhibitors,
some of which are entering clinical trials
(Marone et al., 2008). Mutations resulting
in inhibitor resistance will surely arise.
Can we apply the lessons learned from
the protein kinases to the lipid kinase
PI3K? This is the question asked in a study
published in the current issue of Cancer
Cell (Zunder et al., 2008).
The recently determined structure of
p110a shows some broad similarities to
that of protein kinases, notably a hydro-
phobic cavity that corresponds to the
affinity pocket of protein kinases (Huang
et al., 2007). Several PI3K inhibitors target
this structural motif and therefore could
be affected by resistance mutations simi-
lar to those found in protein kinases.
These basic similarities guided ZunderCancer Celland colleagues (2008) in their study of
drug resistance in PI3K. The researchers
mutagenized selected residues lining
the p110a affinity pocket, including the
homolog of the gatekeeper, I848. The mu-
tants were tested against several PI3K
inhibitors using an ingenious yeast lethal-
ity test. The assay is based on the fact that
Saccharomyces cerevisiae does not con-
tain class I PI3Ks and that expression
of p110a depletes its essential stores
of phosphatidylinositol 4,5-bisphosphate,
thus interfering with cell replication. Inhi-
bition of p110a activity restores growth
and viability of p110a-expressing S. cere-
visiae (Figure 1). The simplicity and
rapidity of the yeast screen allowed cov-
erage of a sizable number of mutant/
inhibitor combinations, including satura-
tion mutagenesis and diverse inhibitor
chemotypes.
The results of these mutagenesis stud-
ies are both unexpected and instructive.
In contrast to the affinity pockets of pro-
tein kinases, which can accommodate
diverse mutations, the pocket of p110a
is relatively intolerant to change. Most
mutations led to a loss of enzymatic activ-
ity. Gatekeeper mutations were another
surprise: not only did they fail to induce
resistance, most of them were also cata-
lytically inactive or retained only minimal
enzymatic activity. A single residue in
the affinity pocket gave rise to resistant14, August 12, 2008 ª2008 Elsevier Inc. 107
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Previewsmutants (I800M and I800L). In addition,
the yeast assay identified mutations that
convey enhanced sensitivity to inhibitors;
one example is L814C. The mutation
I800L is unique in that it induces a split
phenotype: resistance against some in-
hibitors and enhanced sensitivity against
others. The results obtained with yeast
were validated in mammalian systems:
the mutation-induced changes in catalytic
and signaling activities and in resistance
or sensitivity to inhibitors could be faith-
fully reproduced in human cells, in which
the catalytically active mutants retained
oncogenic potential.
We can derive several lessons from this
study. The resistance mutations identified
in the affinity pocket can guide a preemp-
tive strike. It is probably not too early to
start generating small-molecule inhibitors
that are effective against the I800L and
I800M mutants. The L814C mutant,
showing increased sensitivity to inhibi-
tors, is a potentially useful tool for the
study of isoform-specific functions of
p110a. There are currently no isoform-
specific inhibitors available for p110a.
Therefore, cells carrying a knockin-sensi-
tizing mutation could be used with avail-
able compounds at low enough inhibitor
concentrations to analyze the selective
effects on p110a.
Despite the general structural similari-
ties between kinases, there are sharp
differences between protein and lipidThe Ever-Lengthe
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p53 is a pivotal bulwark against c
because itmodulates such diverse b
of Cell, Godar et al. (2008) now ide
cell-surface glycoproteins that coor
As principal cell factotum of stress respon-
ses, sentinel of damage, guardian of the
genome, and scourge of all cancers, the
p53 protein has assumed an almost myth-
108 Cancer Cell 14, August 12, 2008 ª2008kinases. A reflection of these differences
is the pronounced intolerance of the PI3K
affinity pocket to mutation. A functional
Figure 1. Testing for PI3K Inhibitors in
Yeast: The ‘‘Reverse Halo’’ Assay
The two plates contain a lawn of yeast cells that
express p110a and hence fail to grow. A PI3K in-
hibitor spotted on a cellulose disk (orange) diffuses
into the surrounding lawn, inhibits p110a, and re-
stores cell growth (A). A control disk with DMSO
has no effect (B).ning Arm of p53
Family Comprehensive Cancer Center, San Fra
ancer, but exactly how it suppresse
iological processes via somany dow
ntify another string to p53’s antican
dinate many attributes of tumor prog
ological status. Such remarkable attributes
havegarnered p53 muchattention fromthe
scientific community, and, some 46,581
scientific publications later (as of July 21,
Elsevier Inc.explanation of this remarkable inflexibility
remains an important goal for future
research.
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2008), one might be forgiven for thinking
that we know all there is to know about
this eldritch protein. Well, actually, no.
There are just a few questions that remain
